Tags: mounjaro | zepbound | doses | shortage | supply | fda

FDA: Most Mounjaro, Zepbound Doses in Limited Supply

zepbound injection pen in foreground of a pharmacy with shelves of drugs in background
(Dreamstime)

Thursday, 18 April 2024 08:02 AM EDT

Most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the U.S. Food and Drug Administration's website showed on Wednesday.

Both drugs had limited availability for the 5 milligram (mg), 7.5 mg, 10 mg, 12.5 mg and 15 mg doses, the website noted. The 2.5 milligram doses for the treatments were listed as available.

Previously, some doses of both the drugs were expected to be available in limited quantities through April. Doses of Mounjaro have been available in limited amounts since February.

The 1.5 mg and 4.5 mg doses of Trulicity, another diabetes drug by Lilly, will also be available in limited amounts through April due to increased demand, according to the FDA's website.

Increasing demand for a type of highly effective diabetes and weight-loss treatment known as GLP-1 agonists has led to supply constraints for drugmakers such as Lilly and Novo Nordisk. 

"While we anticipate limited availability in the near term, we expect our investments in manufacturing and supply capacity to progressively increase production of our medicines throughout 2024 and beyond," a spokesperson for Lilly said.

The drugmaker has also advised patients to plan ahead for refills of their medicines by contacting their pharmacy at least one week before the refill is needed.

Mounjaro has been approved since 2022 for patients with Type-2 diabetes to control their blood sugar levels. It was approved in the U.S. for weight loss under the brand name Zepbound late last year.

Separately, Lilly said earlier on Wednesday that tirzepatide - the active ingredient in both Mounjaro and Zepbound - helped ease symptoms of a common sleep-related breathing disorder across two late-stage studies. 

© 2024 Thomson/Reuters. All rights reserved.


Health-News
Most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the U.S. Food and Drug Administration's website showed on Wednesday. Both drugs had limited availability...
mounjaro, zepbound, doses, shortage, supply, fda
287
2024-02-18
Thursday, 18 April 2024 08:02 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved